✦ LIBER ✦

Treatment of short bowel patients with glucagon-like peptide 2 (GLP-2), a newly discovered intestinotrophic, anti-secretory, and transit modulating peptide

✍ Scribed by Palle B. Jeppesen; Bolette Hartmann; Jesper Thulesen; Jesper Graff; Birthe S. Hansen; Flemming Tofteng; Jette Lohmann; Steen S. Poulsen; Jan L. Madsen; Jens J. Holst; Per B. Mortensen

Book ID: 119425910
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 304 KB
Volume: 118
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(00)82790-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sa1961 Teduglutide, a Human Recombinant

Sa1961 Teduglutide, a Human Recombinant Analog of Glucagon-Like Peptide-2 (GLP-2), Increases Plasma Citrulline Levels in Patients With Short Bowel Syndrome

✍ Messing, Bernard; Joly, Francisca; Schwartz, Lauren K.; Iyer, Kishore R.; Chu, H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 141 KB

P097 SHORT BOWEL PATIENTS TREATED FOR TW

P097 SHORT BOWEL PATIENTS TREATED FOR TWO YEARS WITH NATIVE GLUCAGON-LIKE PEPTIDE 2 (GLP-2): COMPLIANCE, SAFETY AND EFFECTS ON QUALITY OF LIFE

✍ P.B. Jeppesen; I.B. Gottschalck; J.J. Holst; P.B. Mortensen 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

M1055 Short Bowel Patients Treated for T

M1055 Short Bowel Patients Treated for Two Years with Native Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety and Effects On Quality of Life

✍ Jeppesen, Palle B.; Gottschalck, Ida B.; Holst, Jens J.; Mortensen, Per B. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 96 KB

A dose-equivalent comparison of the effe

A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

✍ Naimi, R.M.; Madsen, K.B.; Askov-Hansen, C.; Brandt, C.F.; Hartmann, B.; Holst, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 215 KB

Acute effects of continuous infusions of

Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study

✍ Madsen, K.B.; Askov-Hansen, C.; Naimi, R.M.; Brandt, C.F.; Hartmann, B.; Holst, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 267 KB

M1824a Two Dose-Equivalent, 56-Days, Sub

M1824a Two Dose-Equivalent, 56-Days, Subcutaneous (s.c.), Glucagon-Like Peptide 2 (GLP-2) Regimens, 1.6 Mg Once Daily (OD) Versus 0.4 Mg Four Times Daily (QID), in the Treatment of Short Bowel Syndrome (SBS) Patients

✍ Jeppesen, Palle B.; Gottschalck, Ida B.; Holst, Jens J.; Mortensen, Per B. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 137 KB